A one-year renewable agreement will let Shimadzu Medical Systems USA market the TIPSO AirPad, potentially safeguaring sterilization in interventional radiology procedures.
Diagnostic medical imaging systems company Shimadzu Corporation announced Monday that its subsidiary Shimadzu Medical Systems USA signed a one-year renewable agreement with Canadian company NZ Technologies to market the TIPSO AirPad® in the U.S. market.
TIPSO technology is largely used in interventional radiology procedures, and, according to a company press release, the AirPad will let providers move images during a procedure without actually touching them. Limiting contact will safeguard sterility as operators won’t need to scrub in and out in order to consult images.
AirPad is a palm-sized, portable, wireless solution that offers multimodal imaging control that uses finger taps and twirls to manage image orientation and adjustments, according to the press release. It sits as a mouse and keyboard at the bedside while a representation of a hand and a menu pops up on the system monitor display.
The AirPad connects to any workstation via a USB dongle without interfacing with the hospital networking or any type of transfer or storage of patient data, helping to maintain HIPAA compliance. By providing ready-access to live and historical images, the technology could reduce the need for additional scans, as well as decrease operative time, the company said.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.